Historically radiation oncologists have been cautious about re-irradiating brain tumours because of concerns about the risks of late central nervous system toxicity, especially radionecrosis, which may occur several months to years after treatment. There is, however, a lack of prospective data addressing this approach. Re-irradiation of brain tumours is attracting more interest as our understanding of the tolerance of the brain to radiation evolves, and developments in radiation technology and imaging make highly accurate targeting of biologically relevant tumour volumes possible. With developments in molecular-targeted therapy, further exploration of the role of re-irradiation on its own or in combination with novel agents is needed.
KeywordsHigh Grade Glioma Stereotactic Radiotherapy Recursive Partitioning Analysis Recurrent Glioma Target Definition
- Dunkel IJ, Gardner SL, Garvin JH Jr et al (2010) High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neurooncology 12:297–303Google Scholar
- Hall EJ, Giaccia AJ (2005) Radiobiology for the radiologist, 6th edn. Lippincott Williams and Wilkins, Philadelphia, PAGoogle Scholar
- Levin VA, Bidaut L, Hou P et al (2010) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. Epub Accessed 15 Apr 2010Google Scholar
- Wick W, Steinbach JP, Kuker WM et al (2007) One week on/one week off regimen of temozolomide: Phase II trial in recurrent glioma. J Clin Oncol ASCO annual meetings proceedings Part 1 25(18S)Google Scholar
- Wong E, Huberman M, Lu X-Q (2008) Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 26:5049Google Scholar